The paradoxical thing about the evidence so far: the published animal data on Epitalon have predominantly shown no increased cancer incidence, some even report a reduced tumour rate (Anisimov et al., 2003)
Probiotics: supporting the gut microbiome Changes in gut motility and digestion affect the microbiome
43 ChenS.BinP.RenW.GaoW.LiuG.YinJ.et al (2017)
And we always are looking for new ideas and we may include you or feature your question in one of our upcoming episodes
When discussing retatrutide with a healthcare professional, it is helpful to: Share your full cardiovascular history , including any previous heart conditions, arrhythmias, or relevant family history Bring a list of your current medications , as the heart rate effects of retatrutide may be relevant where rate-modifying drugs are already prescribed Ask about eligibility for clinical trials , as your GP or specialist may be able to refer you to a trial centre if you meet the inclusion criteria Discuss your overall cardiometabolic risk , including blood pressure, cholesterol, HbA1c, and BMI, to contextualise whether a drug of this class might be appropriate for you in the future For clinicians, current NICE guidance relevant to this area includes NICE CG189 (Obesity: identification, assessment and management), NICE TA875 (Semaglutide for managing overweight and obesity), and NICE NG28 (Type 2 diabetes in adults: management)
Lilly Launches Trulicity in the US First Ever Ready-to-Use Once-Weekly GLP-1 Receptor Agonist Twitter summary: @LillyDiabetes launches Trulicity in the US first ready-to-use once-weekly GLP-1, available w/savings program for commercially insured On November 10, Eli Lilly and company announced that Trulicity (dulaglutide) is now available in the US, making it the first ready-to-use once weekly GLP-1 receptor agonist to reach the market (no mixing required)
